Enovis (ENOV) is back on investors' radar after reaffirming its 2026 revenue guidance of about US$2.31b to US$2.37b and posting first quarter sales of US$589.15m, along with a smaller net loss.

Despite the reaffirmed 2026 guidance and first quarter update, the share price is around US$25.70, with a 90 day share price return of 17.3% but a 1 year total shareholder return that declined 29.0%. This suggests recent momentum following a tougher period.

If you are weighing Enovis against other healthcare related ideas, it could be worth scanning for companies using artificial intelligence in medical applications through 33 healthcare AI stocks

With the stock trading at about US$25.70, a large gap to analyst targets and a value score of 5, the key question is whether Enovis is currently undervalued or if the market is already pricing in its future growth.

Most Popular Narrative: 42.5% Undervalued

At a last close of about $25.70 versus a narrative fair value of roughly $44.73, Enovis is framed as materially discounted, with that gap hinging on specific growth, margin, and cash flow assumptions rather than just sentiment.

The accelerating need for orthopedic care due to an aging and increasingly active global population, as well as the rising prevalence of chronic conditions like obesity and diabetes, is expanding Enovis's addressable market, creating a consistent tailwind for long-term revenue growth.

Read the complete narrative. Read the complete narrative.

Want to see what justifies that higher fair value? The narrative leans on steady revenue compounding, a swing from heavy losses to profit, and a rich future earnings multiple. Curious how those moving parts fit together.

Result: Fair Value of $44.73 (UNDERVALUED)

However, even this upbeat story runs into real-world hurdles, including ongoing integration issues from recent acquisitions and delays around key technology launches that could unsettle the thesis.

Next Steps

If the mixed signals here have you on the fence, take a moment to review the underlying data yourself and decide quickly how you feel about the story before it moves. To see what investors are currently optimistic about, check out the 3 key rewards

Looking for more investment ideas?

If Enovis has caught your attention, do not stop here; broaden your watchlist with a few focused stock ideas that could sharpen your next move.

• Target reliable income potential by checking out companies we flag as 14 dividend fortresses for investors who want yields with staying power.
• Hunt for quality on sale by scanning 46 high quality undervalued stocks that combine strong fundamentals with prices that look out of step with their underlying strength.
• Prioritise resilience first by reviewing 68 resilient stocks with low risk scores that score well on financial stability and business risk, so you are not caught off guard.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.